A detailed history of Armstrong Advisory Group, Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Armstrong Advisory Group, Inc holds 100 shares of HALO stock, worth $4,754. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100
Holding current value
$4,754
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$51.3 - $64.42 $5,130 - $6,442
100 New
100 $5,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.62B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Armstrong Advisory Group, Inc Portfolio

Follow Armstrong Advisory Group, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armstrong Advisory Group, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Armstrong Advisory Group, Inc with notifications on news.